Investors Urged to Act as Deadline Approaches in Altimmune Securities Fraud Case

Latest Update on Altimmune Securities Fraud Lawsuit

A national law firm, Berger Montague PC, has announced a significant class action lawsuit against Altimmune Inc., a company listed on NASDAQ under the ticker ALT, aimed at investors who acquired shares between August 10, 2023, and June 25, 2025. With the deadline for potential plaintiffs looming on October 6, 2025, the firm is urging impacted investors to take action.

Background of Altimmune Inc.

Based in Gaithersburg, Maryland, Altimmune is a clinical-stage biopharmaceutical company that is dedicated to developing innovative therapies primarily focused on treating obesity and liver diseases. Notably, one of their projects targets metabolic dysfunction-associated steatohepatitis (MASH), a disease characterized by severe liver inflammation and damage.

The lawsuit arises from the company's public release on June 26, 2025, which revealed disappointing results from its IMPACT Phase 2b trial concerning Pemvidutide, a treatment for MASH. Despite prior positive indications from company executives, the trial found no significant statistical advantages in the primary endpoint for fibrosis reduction, attributed to an unexpectedly high placebo effect. Consequently, Altimmune's stock price fell drastically by 53.2% in a single day, plummeting from $7.71 to $3.61.

Impacts of the Stock Price Drop

This remarkable share price decrease highlights the potential misrepresentation of clinical trial data that many investors argue could have influenced their investment decisions. The lawsuit alleges that Altimmune's management failed to provide valid updates about the trial's outcomes, which could have prompted investors to reconsider their stake in the company. As a result of this loss, those who purchased shares during the speculated class period are advised to determine their eligibility to join the class action.

Why Join the Class Action?

Participating in this class action might not only assist stakeholders in recovering losses, but it can also ensure that corporations are held accountable for transparent communication about their initiatives. Investors are encouraged to familiarize themselves with their rights and explore options for potentially being appointed as lead plaintiffs.

Berger Montague, with its extensive experience in securities litigation since 1970, represents a trusted ally for investors navigating these distressed waters. Contact options for affected investors include the firm's lead counsels, Andrew Abramowitz at [email protected] and Caitlin Adorni at [email protected].

As the deadline for involvement in this lawsuit approaches, it is imperative for those affected to make informed decisions. All impacted investors are urged to consider joining forces to seek restitution for the losses endured due to the unexpected downturn in Altimmune's financial outlook.

Contact Information

To learn more or to discuss your rights regarding the lawsuit, affected investors can visit the Berger Montague’s website or reach out to their legal representatives directly through the provided contact details.

This lawsuit against Altimmune Inc. serves as a reminder of the volatility inherent in biopharmaceutical investments, particularly as they relate to trial outcomes and the consequential impacts on stock valuations. Participation is vital, and understanding the ramifications of corporate announcements can play a crucial role in safeguarding investor interests.